Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (7): 791-795.doi: 10.12092/j.issn.1009-2501.2020.07.011

Previous Articles     Next Articles

Progress on TMPRSS2-ERG fusion gene product transcription regulation mechanism in prostate cancer cells

CAO Ying, TU Linglan, WANG Xiaoju, ZHENG Xiaoliang   

  1. Center for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou 310013, Zhejiang, China
  • Received:2020-03-12 Revised:2020-06-04 Online:2020-07-26 Published:2020-07-31

PDF (PC)

171

Abstract: Prostate cancer is the most common malignant tumor in men in Europe and the United States, but the mechanism of prostate cancer occurrence and development is not completely clear. In prostate cancer, the TMPRSS2-ERG fusion gene has a high incidence, which promotes ERG overexpression and causes changes in target genes and signaling pathways, such as androgen receptors, spotted zinc finger structural proteins, Notch pathways. In-depth understanding of the transcriptional regulation mechanism of TMPRSS2-ERG fusion gene products in prostate cancer cells can provide new targets for drug action in the treatment of prostate cancer.

Key words: prostate cancer, TMPRSS2-ERG fusion gene, androgen receptors, spotted zinc finger structural proteins, Notch pathways

CLC Number: